Skin autofluorescence - A tool to identify type 2 diabetic patients at risk for developing microvascular complications

被引:205
作者
Gerrits, Esther G. [1 ]
Lutgers, Helen L. [2 ]
Kleefstra, Nanne [1 ,3 ]
Graaff, Reindert [4 ]
Groenier, Klaas H. [5 ]
Smit, Andries J. [2 ,6 ]
Gans, Rijk O. [2 ,6 ]
Bilo, Henk J. [1 ,2 ,6 ]
机构
[1] Isala Clin, Ctr Diabet, NL-8000 GK Zwolle, Netherlands
[2] Univ Med Ctr Groningen, Dept Med, NL-9713 AV Groningen, Netherlands
[3] Langerhans Med Res Grp, Zwolle, Netherlands
[4] Univ Med Ctr Groningen, Dept Biomed Engn, NL-9713 AV Groningen, Netherlands
[5] Univ Med Ctr Groningen, Dept Gen Practice, NL-9713 AV Groningen, Netherlands
[6] Univ Groningen, Dept Med, Groningen, Netherlands
关键词
D O I
10.2337/dc07-1755
中图分类号
R5 [内科学];
学科分类号
1002 [临床医学]; 100201 [内科学];
摘要
OBJECTIVE - Skin auto fluorescence is a noninvasive measure of the level of tissue accumulation of advanced glycation end products, representing cumulative glycemic and oxidative stress. Recent studies have already shown a relationship between skin autofluorescence and diabetes complications, as well as the predictive value of skin autofluorescence for total and cardiovascular mortality in type 2 diabetes. Our aim was to investigate the predictive value of skin autofluorescence for the development of microvascular complications in type 2 diabetes. RESEARCH DESIGN AND METHODS - At baseline, skin autofluorescence of 973 type 2 diabetic patients with well-controlled diabetes was noninvasively measured with an autofluorescence reader. The aggregate clinical outcome was defined as the development of any diabetes-associated microvascular complication of 881 surviving patients, which was assesse at baseline and at the end of follow-up. Single end points were the development of diabetes-sassociated retinopathy, neuropathy, and (micro)albuminuria. RESULTS - After a mean follow-up period of 3.1 years, baseline skin autofluorescence was significantly higher in patients who developed any microvascular complication, neuropathy, or (micro) albuminuria but not in those who developed retinopathy. Multivariate analyses showed skin auto fluorescence as a predictor for development of any microvascular complication along with AlC, for development of neuropathy along with smoking, and for development of (micro)albuminuria together with sex, AlC, and diabetes duration. Skin autofluorescence did not have predictive value for the development of retinopathy, albeit diabetes duration did. CONCLUSIONS - Our study is the first observation of skin autofluorescence measurement as an independent predictor of development of microvascular complications in type 2 diabetes.
引用
收藏
页码:517 / 521
页数:5
相关论文
共 21 条
[1]
Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): prospective observational study [J].
Adler, AI ;
Stratton, IM ;
Neil, HAW ;
Yudkin, JS ;
Matthews, DR ;
Cull, CA ;
Wright, AD ;
Turner, RC ;
Holman, RR .
BMJ-BRITISH MEDICAL JOURNAL, 2000, 321 (7258) :412-419
[2]
Role of vascular endothelial growth factor in diabetic vascular complications [J].
Aiello, LP ;
Wong, JS .
KIDNEY INTERNATIONAL, 2000, 58 :S113-S119
[3]
*AM DIAB ASS, DIAB DICT
[4]
[Anonymous], 2006, HUISARTS WET
[5]
The pathobiology of diabetic complications - A unifying mechanism [J].
Brownlee, M .
DIABETES, 2005, 54 (06) :1615-1625
[6]
Fitzpatrick T. B., 1975, J MED ESTHETIQUE, P33, DOI DOI 10.1159/000251345
[7]
THE VALIDITY AND PRACTICALITY OF SUN-REACTIVE SKIN TYPE-I THROUGH TYPE-VI [J].
FITZPATRICK, TB .
ARCHIVES OF DERMATOLOGY, 1988, 124 (06) :869-871
[8]
Glycation and carboxymethyllysine levels in skin collagen predict the risk of future 10-year progression of diabetic retinopathy and nephropathy in the diabetes control and complications trial and epidemiology of diabetes interventions and complications participants with type 1 diabetes [J].
Genuth, S ;
Sun, WJ ;
Cleary, P ;
Sell, DR ;
Dahms, W ;
Malone, J ;
Sivitz, W ;
Monnier, VM .
DIABETES, 2005, 54 (11) :3103-3111
[9]
HILO HJG, 2006, NIV CBO DUTCH NATL D
[10]
Kawahara M, 2000, NEURO-OPHTHALMOLOGY, V23, P1